Physician profile
Lauren E Shoemaker
NPI 1821440777
$1,934.83
in general payments reported to CMS, 2019-2025
25 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.63 · 2021: $67.37 · 2022: $317 · 2023: $466 · 2024: $513 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $376.04 | 2023-2025 | |
| Novo Nordisk INC | $236.25 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $196.22 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $146.83 | 2022-2025 | Rexulti |
| Amgen INC. | $139.48 | 2020-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.16 | 2021-2024 | Tradjenta, Synjardy, Jardiance |
| Abbvie INC. | $93.15 | 2021-2025 | Ubrelvy |
| Astellas Pharma US INC | $88.20 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $75.84 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $64.09 | 2023 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $49.06 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.07 | 2023-2025 | |
| Exact Sciences Corporation | $42.73 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $34.19 | 2022 | |
| Gilead Sciences, INC. | $32.12 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.06 | 2022-2023 | |
| Pulmonx Corporation | $27.12 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.35 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $21.05 | 2022 | |
| Irhythm Technologies, INC. | $18.77 | 2022 | |
| Dynavax Technologies Corporation | $17.56 | 2024 | Heplisav-B |
| Actelion Pharmaceuticals US, INC. | $17.54 | 2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $16.98 | 2024 | |
| Abbott Laboratories | $16.44 | 2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $8.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.